South Korea's Outdated Diabetes Drug Policy Hinders Patient Care

South Korea is grappling with an outdated insurance policy for diabetes medications, which has remained unchanged for 15 years, creating a significant hurdle for the nation's estimated 6 million adults living with diabetes. While medical guidelines have evolved to recommend more personalized and proactive treatment strategies, the existing insurance framework, established in 2011, fails to keep pace.

“

The 'General Principles for Insurance Coverage of Diabetes Medications' established in 2011 has remained stuck in its existing framework for 15 years, creating a structural limitation where prescriptions are made within limited options.

The latest clinical guidelines emphasize the importance of early, intensive treatment, particularly for patients with comorbidities such as heart failure, chronic kidney disease, and atherosclerotic cardiovascular disease. These guidelines recommend the early use and combination of SGLT2 inhibitors and GLP-1 receptor agonists. However, the current insurance policy's rigid structure, which prioritizes metformin as the initial treatment and dictates a sequential approach to adding other medications, limits access to these more advanced and potentially more effective therapies.

“

The gap between insurance coverage criteria and clinical guidelines is widening, leading to a repeated situation where patients cannot receive the most appropriate treatment in a timely manner.

Experts from the Korean Diabetes Association and the Korea Medical & Bio-Journalist Association convened to discuss the urgent need for reform. They highlighted that the 2011 "General Principles for Insurance Coverage of Diabetes Medications" hinders personalized treatment by not reflecting the latest clinical evidence. Dr. Cho Young-min, Head of the Guideline Committee at the Korean Diabetes Association, explained that the focus has shifted from solely managing blood sugar levels to preventing complications and improving long-term outcomes. He argued that applying metformin universally as a first-line treatment is not patient-centered when other drugs have proven benefits for specific patient profiles.

“

Now is the time to actively apply these treatments, which have sufficient clinical evidence, to diabetes patients from the beginning.

The proposed revisions include greater flexibility in first-line treatment options, prioritizing SGLT2 inhibitors and GLP-1 receptor agonists based on comorbidities, expanding combinations of rational drug therapies, and revising criteria for insulin and GLP-1 receptor agonists. The current system often forces treatment decisions based on what is covered by insurance rather than what is clinically most appropriate, delaying timely and effective care for patients. Revising these guidelines is seen as crucial for ensuring that South Korean diabetes patients can receive the most up-to-date and beneficial treatments available.

“

Although domestic and international guidelines have shifted towards selecting appropriate drugs based on a patient's condition and comorbidities, coverage standards have not reflected this.